NSE: STAR | BSE: 532531

Strong Performer, Under Radar

Download real time

797.75 -6.65 (-0.83%)

52.37% Fall from 52W High

195.7K NSE+BSE Volume

NSE 11 Aug, 2025 3:31 PM (IST)

7,353.1

Market Cap

Above industry Median

1.1

Beta 1Year

High Volatility

Strides Pharma Science Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for STAR, BSE:532531 Strides Pharma Science Ltd.

Search Inside the pdf :

Strides Pharma Science Ltd.

24 Oct 2024

797.75

-0.83%

Continued momentum with another strong quarter

Buy: Strides Pharma Science Ltd.

Target

Sharekhan

Q2FY25 revenues totaling Rs. 1,201 crore, demonstrating a significant y-o-y growth rate of 20%.EBITDA stood at Rs. 236 crore, marking a remarkable y-o-y increase of 31%.

Strides Pharma Science Ltd. is trading above its 150 day SMA of 724.8

Strides Pharma Science Ltd.

27 Aug 2024

797.75

-0.83%

STRIDES PHARMA SCIENCE LIMITED

Sell: Strides Pharma Science Ltd.

Recommendation Target

Geojit BNP Paribas

Promoters unpledged 1.88% of shares in last quarter. Total pledge stands at 50.10% of promoter holdings

Strides Pharma Science Ltd.

26 Dec 2023

797.75

-0.83%

STRIDES PHARMA SCIENCE LIMITED

Accumulate: Strides Pharma Science Ltd.

Recommendation Target

Geojit BNP Paribas

Strides Pharma Scien.. has an average target of 1524.50 from 2 brokers.

Strides Pharma Science Ltd.

31 Oct 2023

797.75

-0.83%

Mixed results, divestment to revitalize operating performance

Hold: Strides Pharma Science Ltd.

Recommendation

ICICI Securities Limited

Strides Pharma Science (Strides)’s Q2FY24 revenue growth (up 11% YoY) was better, though EBITDA margins (adj. margins at 16.8%) were a tad weaker than anticipated. Revenue growth in the quarter was driven by other regulated markets (35% YoY) and Africa (up 36%). Strides is re-grouping its CDMO business under one umbrella ‘Onesource’ – this entity will likely clock revenues of USD 400mn in FY27, from USD 150mn in FY24E.

Number of FII/FPI investors increased from 268 to 287 in Jun 2025 qtr.

Strides Pharma Science Ltd.

26 Sep 2023

797.75

-0.83%

Regrouping CDMO pieces to unlock value

Sell: Strides Pharma Science Ltd.

Recommendation Target

ICICI Securities Limited

Strides Pharma (Strides) is streamlining its CDMO business by merging its soft gel capsule business and injectable business of Steriscience with Stelis. It will also rename Stelis to OneSource after completion, and regrouping will help the promoter better align the focus on all the arms of the CDMO business. The combined entity is likely to have revenue of USD 180-200mn in FY25E and management expects to grow 20-25% p.a. thereon.

Strides Pharma Science Ltd. has gained 24.95% in the last 3 Months

Strides Pharma Science Ltd.

03 Aug 2023

797.75

-0.83%

Striving to improve margin; valuations pricey

Hold: Strides Pharma Science Ltd.

Recommendation Target

ICICI Securities Limited

Strides Pharma Science’s (Strides) Q1FY24 earnings exhibited a healthy beat on margin front. Improved product mix, cost-optimisation initiatives and freight costs led to expansions in gross margin (+880bps YoY) and EBITDA margin (+1,250bps). Management aspires to improve from these levels going ahead. Adjusted for divested businesses, revenue recorded a healthy 11% YoY growth.

Strides Pharma Science Ltd. is trading below its 30 day SMA of 876.6

Strides Pharma Science Ltd.

01 Jun 2023

797.75

-0.83%

Strides Pharma

Buy: Strides Pharma Science Ltd.

Sharekhan

Promoters unpledged 1.88% of shares in last quarter. Total pledge stands at 50.10% of promoter holdings

Strides Pharma Science Ltd.

28 Feb 2023

797.75

-0.83%

STRIDES PHARMA SCIENCE LIMITED

Buy: Strides Pharma Science Ltd.

Recommendation Target

Geojit BNP Paribas

Strides Pharma Science Ltd. has lost -30.19% in the last 1 Year

Strides Pharma Science Ltd.

25 Jan 2023

797.75

-0.83%

Regulated markets drive growth

Buy: Strides Pharma Science Ltd.

Target

ICICI Securities Limited

Strides Pharma Science’s (Strides) Q3FY23 performance fell short of our revenue expectations, mainly due to negligible sales in the institutional business. Revenues grew 8.9% YoY (-3.6% QoQ) to Rs.8.7bn (I-Sec: Rs10bn).

Number of FII/FPI investors increased from 268 to 287 in Jun 2025 qtr.

Is Strides Pharma Science Ltd. worth buying?

489 Votes:

Buy 78.73%

Sell 11.86%

Hold 9.41%

RESEARCH REPORTS

Buy SEE REPORTS >

pdf

Sell SEE REPORTS >

pdf